For the drugs of the future, Eli Lilly is seeking fortune in China.
Eli Lilly has signed a $2 billion agreement with Hong Kong biotech company Insilico Medicine for the development of drugs using artificial intelligence, a trend also pursued by other major pharmaceutical companies. Facts, figures, and comments.
